About Centese
Centese is a Healthcare company based in Omaha (United States) founded in 2016 by Evan Luxon. Surgical drainage systems are developed and manufactured by Centese. Centese has raised $18.7 million across 7 funding rounds from investors including MedTech Venture Partners and Invest Nebraska. Its chief executive, as recorded, is Evan Luxon. Centese offers products and services including Thoraguard. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Surgical Devices. Its legal entity is Centese, Inc. Its competitors include Cardioptimus, Neoolife and Pressure Products.
Company details
Centese was founded in 2016 in Omaha, United States, within the medical devices sector. A surgical drainage system known as Thoraguard is produced, featuring integration with sensors and software. Clinical staff are notified of leakages via alarms, while automated suction management and drainage output tracking are enabled. Clog-free chest tubes are incorporated into the design for reliable operation in healthcare settings.
- Headquarters Omaha, United States
- Founders Evan Luxon
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website centese.com
- Social LinkedIn X
- Legal Name Centese, Inc.
- Total Equity Funding$18.7M (USD)
in 7 rounds
- Latest Funding Round$250K (USD), Series B
May 2026
- InvestorsMedTech Venture Partners
& 1 more
Products & Services of Centese
Centese offers a comprehensive portfolio of products and services, including Thoraguard.
Provides digital monitoring and automated clearance for chest tubes.
Funding Insights of Centese
Centese has successfully raised a total of $18.7M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $250 thousand completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.7M
- Total Rounds 7
- Last Round Series B — $250,000
- Investors Count 2
All 7 funding rounds of Centese with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | Debt – Conventional | – | – | – | |
| May 2026 | $250,000 | Series B | – | – | – |
| May 2025 | Debt – Conventional | – | – | – | |
| May 2025 | $525,000 | Series B | – | – | – |
| Nov 2023 | $15M | Series B | – | Medical Technology Venture Partners | – |
| Nov 2017 | $2.93M | Seed | – | – | – |
| Jun 2016 | Seed | – | Invest Nebraska | – |
2 investors in total: 2 institutional.
Investors in Centese
Centese has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include MedTech Venture Partners and Invest Nebraska.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
MedTech Venture Partners is focused on medical technology investments. | medtechvp.com | Menlo Park, United States | ||
Early stage VC firm investing in the US | investnebraska.com | Lincoln, United States |
Investor details for Centese
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Centese
4 people are tracked at Centese (3 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Evan Luxon | Co-Founder & CEO | Leadership |
Heath S. | Director Of Quality | Leadership |
Randy Preston | Chief Business Officer | Leadership |
Ryan Coughlin | Engineering Manager | Team |
Complete people profiles for Centese
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Centese
3 dated milestones of Centese across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Centese is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $250K.
Competitors of Centese
Centese has 3 listed competitors in our database. They include Cardioptimus, Neoolife and Pressure Products.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cardioptimus.weebly.com | 2006 | Columbia, United States | Removable stents for cardiac surgeries are developed and provided. | |||
| neoolife.com | 2020 | Pittsburgh, United States | Developer of a device for cardiovascular disease treatment | |||
| pressure-products.com | 1987 | Los Angeles, United States | Provides medical devices for vascular access and cardiac rhythm management procedures. |
Detailed competitors of Centese
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Centese
The website of Centese (centese.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▲ 50% vs previous month
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Centese (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Centese
Complete news archive for Centese
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Centese
Centese was founded in 2016.
Centese is headquartered in Omaha, United States. It is registered at Omaha, Nebraska, United States.
Evan Luxon is the CEO of Centese, as recorded in our data. They have also founded this company.
Centese is a funded company, having raised a total of $18.7M across 7 funding rounds to date.
Centese was founded in 2016 in Omaha, United States, within the medical devices sector. A surgical drainage system known as Thoraguard is produced, featuring integration with sensors and software. Clinical staff are notified of leakages via alarms, while automated suction management and drainage output tracking are enabled. Clog-free chest tubes are incorporated into the design for reliable operation in healthcare settings.
Centese's top competitors include Neoolife, Cardioptimus and Pressure Products.
Centese offers Thoraguard.
Centese has 2 investors. Key investors include MedTech Venture Partners, and Invest Nebraska.
Centese operates through Centese, Inc..